KDM4A and pancreatic neoplasm: SIRT2 acts as a tumor suppressor and an oncogene [55]; it interacts with β-catenin and lysine-specific demethylase 4A (KDM4A) to inhibit cell growth, and is involved in survival and cell proliferation in pancreatic cancer, hepatocarcinoma, and neuroblastoma [55,56].